ALETA-001
- Generic Name
- ALETA-001
A Phase I/II Trial of ALETA-001 for the Treatment of Participants with B-cell Malignancies
Phase 1
Recruiting
- Conditions
- Lymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, FollicularLymphoma, B-Cell
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 72
- Registration Number
- NCT06045910
- Locations
- 🇬🇧
University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧Cambridge University Hospitals, Cambridge, United Kingdom
🇬🇧St James's University Hospital, Leeds, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath